Format

Send to

Choose Destination
Expert Rev Clin Immunol. 2017 Oct;13(10):1001-1015. doi: 10.1080/1744666X.2017.1366315. Epub 2017 Aug 23.

Immunotherapy of cancers comes of age.

Author information

1
a Research Center for Immunodeficiencies, Children's Medical Center , Tehran University of Medical Sciences , Tehran , Iran.
2
b Department of Endodontics, Dental Branch , Tehran Azad University , Tehran , Iran.
3
c Memorial Sloan Kettering Cancer Center , New York , NY , USA.
4
d Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN) , Tehran , Iran.
5
e Students' Scientific Research Center , Tehran University of Medical Sciences , Tehran , Iran.
6
f Charles River Laboratories , Wilmington , MA , USA.
7
g Department of Immunology, School of Medicine , Tehran University of Medical Sciences , Tehran , Iran.
8
h Network of Immunity in Infection , Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN) , Boston , MA , USA.

Abstract

Cancer immunotherapy has evolved and is aimed at generating the efficacious therapeutic modality to enhance the specificity and power of the immune system to combat tumors. Areas covered: Current efforts in cancer immunotherapy fall into three main approaches. One approach is through the blockade of immune checkpoints, another approach is through adoptive cellular therapy, and the last approach is through vaccination. The goal of this review is to summarize the current understanding and status of cancer immunotherapy in these three categories. Expert commentary: We foresee the development of therapeutic protocols combining these approaches with each other or conventional therapies to achieve the most appropriate guideline for management of cancer.

KEYWORDS:

Cancer immunotherapy; adoptive cellular therapy; bispecific antibodies; chimeric antigen receptors; dendritic cell; immune checkpoint blockade; therapeutic cancer vaccine

PMID:
28795649
DOI:
10.1080/1744666X.2017.1366315
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center